stockrow
Saturday 7 November 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
6.02
0.17
+2.91%
Follow ALMS
Alert me
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | — | — |
Altman Z-Score |
(1.43) | — | — |
P/S ratio |
34.51 | — | — |
Altman Z″-Score (non-manufacturers) |
(7.78) | — | — |
P/FCF ratio |
0.00 | — | — |
P/Operating CF |
(11.54) | — | — |
P/B ratio |
2.75 | — | — |
Price to Tangible BV |
3.32 | — | — |
EV/Sales |
21.68 | — | — |
EV/EBITDA |
0.00 | — | — |
EV/Operating CF |
(1.41) | — | — |
EV/FCF |
(1.41) | — | — |
Quick Ratio |
4.21 | 5.66 | 2.35 |
Current Ratio |
4.34 | 6.01 | 2.56 |
Net Debt/EBITDA |
0.69 | 0.97 | 0.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.00 | — |
Operating CF/Net income |
1.52 | 0.87 | 0.84 |
Capex/Depreciation |
(0.19) | (0.55) | (3.50) |
| (86.68%) | 743.43% | 0.00% | |
| (64.63%) | (136.66%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(92.48%) | (106.51%) | (282.18%) |
Average Days of Receivables |
0.00 | — | — |
Research and Development Expense of Revenue |
1,604.98% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
381.94% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.12 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
180.97% | 0.00% | 0.00% |
Graham Net Nets |
0.25 | — | — |
Graham Number |
0.00 | — | — |
Earnings Yield |
(30.56%) | — | — |
Free Cash Flow Yield |
(44.61%) | — | — |
Revenue per Share |
0.28 | 0.00 | 0.00 |
Operating CF per Share |
(4.35) | (9.00) | (60.45) |
Capex per Share |
(0.01) | (0.06) | (2.09) |
Free Cash Flow per Share |
(4.35) | (9.06) | (62.54) |
Cash per Share |
3.63 | 10.17 | 22.82 |
Shareholders Equity per Share |
3.54 | 9.18 | (157.78) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
3.54 | 9.18 | (157.78) |
Free Cash Flow |
(370.18) | (256.81) | (134.47) |
Working Capital |
244.91 | 255.28 | 32.49 |
Capital Expenditures |
(0.65) | (1.73) | (4.50) |
Net Current Asset Value |
207.59 | 225.30 | (375.51) |
EV/EBIT |
0.00 | — | — |
Capex to Sales |
0.03 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — |
| Other line items | |||
Depreciation/Fixed assets |
0.19 | 0.15 | 0.06 |
Cash ROIC |
(60.70%) | (46.83%) | 46.34% |
Accounts Receivable Turnover |
0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
9.87 | 5.37 | — |
Average Assets |
376.47 | 215.30 | — |
Average Common Equity |
280.70 | (39.58) | — |
Columns are period end dates · fundamentals updated 26 Oct 2026